Navigation Links
Hyperthermia With Chemotherapy Improves Sarcoma Healing

Co-operation between GSF and clinic improves outlook for sarcoma patients: Effectiveness of local, deep hyperthermia proved in phase III study .

Hyperthermia, combined with chemotherapy, improves the chances of healing and survival of patients with low-lying, soft tissue sarcomas.

At the Annual General Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, which ended last week, the GSF scientist, Prof. Dr Rolf D. Issels, presented the results of the first, randomised, worldwide phase III study in which the effectiveness and superiority of the combined-therapy methods are proven, in comparison with results from chemotherapy alone.

The study of 341 high-risk patients with deep, local sarcomas shows a significant improvement in the response of the tumour and in the survival of those patients who were treated by means of a combination of chemotherapy and of local, deep hyperthermia, in addition to operative removal of the sarcoma. This combined therapy has been applied already to a large number of patients in advance of surgery.

The well respected study results from the Clinical Co-operation Group Hyperthermia, which has existed since 1999 between the GSF National Research Centre for Environment and Health in Munich-Neuherberg and the Grohadern Medical Centre of the University of Munich.

Their spectrum of research extends from clinical analysis of deep hyperthermia for cancer therapy up to biological research in the areas of immunobiology and cell biology.

The head of the Clinical Co-operation Group Hyperthermia, Prof. Dr Rolf Issels, has been working at GSF, since the mid-80s, on the use of local, deep hyperthermia as a cancer therapy.

From the beginning, tumours of soft tissues and bones, which start from the connective tissue and are called sarcomas, were taken as examples.

The scientists were especially interested together with related bi ological research - in the question whether certain sarcomas could be better treated with a combination of hyperthermia and other forms of therapy.

In the course of local, deep hyperthermia, tumours are warmed to 40-44 Celsius, with, the aid of electromagnetic waves. At temperatures of 42 C, cells begin to die, on account of the heat. The combination therapy developed at GSF and the Grohadern Medical Centre exploits the fact that tumour cells are more vulnerable at 40 C to the immune system and also to radiotherapy and chemotherapy.

In the past years, the results gained in the treatment of sarcomas have encouraged the research group to apply their knowledge to other forms of tumour.

At the present time, within the framework of a part body hyperthermia project plan, they are investigating whether the combination of chemotherapy and radiotherapy with hyperthermia leads to better treatment results in cases of colon and rectum cancers and of pancreatic carcinoma, as well.

Under the guidance of GSF, a Virtual Institute of Excellence has been founded between the Clinical Co-operation Group Hyperthermia at the Grohadern Medical Centre and the Medical Clinic Charite Berlin, in order to promote the project plan, which will initially be sponsored for three years by the Initiative and Networking Fund of the Helmholtz Association of German Research Centres.

The Scientific Technical Director of GSF, Prof. Dr Wess, regards this as a successful example of translational research. The concept of research in co-operation groups together with clinical partners and the creation of clinical research platforms is an essential prerequisite for the prompt application of knowledge from fundamental research to clinical practice and vice versa.

Contact the GSF Press Office: GSF - Forschungszentrum fr Umwelt und Gesundheit Abteilung Kommunikation Tel: 089/3187-2460 Fax 089/3187-3324 E-mail: oea@gsf. de


'"/>




Related medicine news :

1. Research Reveals Way to Speed Up Treatment of Deadly Malignant Hyperthermia
2. Acupuncture May Help Chemotherapy Side Effects
3. Chemotherapy Pill Has Fewer Side Effects Than IV
4. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. New Method Of Delivering Chemotherapy
8. The Benefits Of Chemotherapy For Women With Ovarian Cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Treating Testicular Cancer With A Single Dose Of Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
Breaking Medicine Technology: